{"id":9262,"date":"2024-11-29T18:19:53","date_gmt":"2024-11-29T12:49:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9262"},"modified":"2024-12-02T10:29:06","modified_gmt":"2024-12-02T04:59:06","slug":"non-small-cell-lung-cancer-market-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2","title":{"rendered":"Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d9d73e03a43\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d9d73e03a43\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#Non-small_Cell_Lung_Cancer_Epidemiology\" >Non-small Cell Lung Cancer Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#Non-small_cell_lung_cancer_Market_Diagnosis_and_current_therapies\" >Non-small cell lung cancer Market: Diagnosis and current therapies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#Diagnosis\" >Diagnosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#Current_Therapies\" >Current Therapies<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#Marketed_Drugs_for_NSCLC\" >Marketed Drugs for NSCLC<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\/#In_the_NSCLC_Pipeline\" >In the NSCLC Pipeline<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p class=\"has-drop-cap\">Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-epidemiology-forecast\">NSCLC incidence<\/a> all over the world. In <strong>2022, <\/strong>there were an estimated <strong>20 million <\/strong>new cancer cases and <strong>9.7 million cancer-related deaths<\/strong>. The number of people living for at least five years after a cancer diagnosis was estimated at <strong>53.5 million. <\/strong>About <strong>1 in 5 individuals<\/strong> will develop cancer in their lifetime, with <strong>approximately 1 in 9 men and 1 in 12 women<\/strong> succumbing to the disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-non-small-cell-lung-cancer-epidemiology\"><span class=\"ez-toc-section\" id=\"Non-small_Cell_Lung_Cancer_Epidemiology\"><\/span><strong>Non-small Cell Lung Cancer Epidemiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Non-small Cell Lung Cancer (NSCLC) <\/strong>accounts for <strong>80-85% of all lung cancer cases, <\/strong>making it the most prevalent subtype. In 2023, the United States saw approximately <strong>200K new cases of lung cancer, <\/strong>including <strong>117K cases in men and 120K in women.<\/strong> Lung cancer remains a significant health concern, with NSCLC outpacing the less common Small Cell Lung Cancer (SCLC), which comprises <strong>10-15% of cases.<\/strong><\/p>\n\n\n\n<p>NSCLC is further categorized into three main histological subtypes: adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. Adenocarcinoma, originating in the glandular cells of the lung, represents around <strong>40% of all lung cancer cases.<\/strong> Squamous cell carcinoma, arising from the flat cells lining the airways, accounts for <strong>25-30%<\/strong>, while large cell carcinoma, an undifferentiated form, comprises approximately <strong>10-15% of cases.<\/strong><\/p>\n\n\n\n<p>Genetic mutations and biomarkers play a crucial role in the diagnosis and treatment of NSCLC. The most frequent biomarkers include <strong>EGFR mutations (64%), ALK rearrangements (60%), PD-L1 expression (48%), ROS1 mutations (46%), and BRAF mutations (40%). Other notable biomarkers such as MET (35%), KRAS (29%), RET (22%), HER2 (21%), and PIK3CA (20%) <\/strong>are also significant in guiding targeted therapies. These genetic markers help tailor treatment plans, improving outcomes for patients with advanced or metastatic disease.<\/p>\n\n\n\n<p>The epidemiology and treatment patterns of <strong>NSCLC <\/strong>are studied across the <strong>7MM (United States, EU4, United Kingdom, and Japan), covering data from 2020 to 2034.<\/strong> This data highlights trends in incidence, histological subtypes, stages at diagnosis, and the growing impact of personalized therapies targeting genetic mutations. With a robust focus on these factors, advancements in treatment are helping redefine the standard of care for NSCLC patients worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-non-small-cell-lung-cancer-market-diagnosis-and-current-therapies\"><span class=\"ez-toc-section\" id=\"Non-small_cell_lung_cancer_Market_Diagnosis_and_current_therapies\"><\/span><strong>Non-small cell lung cancer Market: Diagnosis and current therapies  <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnosis\"><\/span><strong>Diagnosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Non-small cell lung cancer (NSCLC) accounts for <strong>81% of all lung cancer diagnoses<\/strong>, making it the most common form of lung cancer. Early diagnosis is crucial for improving prognosis. However, NSCLC is often challenging to detect in its initial stages due to symptoms that may mimic those of common respiratory illnesses or the effects of long-term smoking. Consequently, approximately <strong>80% of <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-epidemiology-forecast\">NSCLC cases are diagnosed<\/a> <\/strong>at advanced stages, making treatment more complex.<\/p>\n\n\n\n<p>To diagnose NSCLC, physicians typically recommend imaging tests such as <strong>CT, PET, or MRI scans <\/strong>to identify abnormalities in and around the lungs. A sample of mucus may also be collected for microscopic examination. If these tests suggest cancer, further diagnostic procedures, including a lung biopsy or bronchoscopy, may be conducted. <a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchoscope-market\">Bronchoscopy<\/a> allows the physician to visualize lung tissues directly and collect samples for analysis.<\/p>\n\n\n\n<p>Once NSCLC is confirmed, genetic testing of lung tissue is essential to understanding the cancer\u2019s molecular characteristics, which can help tailor treatment options.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"561\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png\" alt=\"Non-Small Cell Lung Cancer Market Key Insights\" class=\"wp-image-30472\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1024x561.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-300x164.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-150x82.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-768x421.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-1536x841.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181141\/Non-Small-Cell-Lung-Cancer-Market-Key-Insights-2048x1122.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Therapies\"><\/span><strong>Current Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Treatment for NSCLC depends on factors such as the cancer\u2019s type and stage, side effects of treatment, and the patient\u2019s overall health and preferences. Common treatment approaches include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Surgery<\/strong><\/li>\n\n\n\n<li><strong>Radiotherapy<\/strong><\/li>\n\n\n\n<li><strong>Chemotherapy<\/strong><\/li>\n\n\n\n<li><strong>Chemoradiotherapy (combination of chemotherapy and radiotherapy)<\/strong><\/li>\n\n\n\n<li><strong>Immunotherapy<\/strong><\/li>\n\n\n\n<li><strong>Targeted cancer drugs<\/strong><\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Marketed_Drugs_for_NSCLC\"><\/span><strong>Marketed Drugs for NSCLC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>KEYTRUDA (pembrolizumab)<\/strong> \u2013 <strong>Merck<\/strong><strong><br><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/keytruda-emerging-drug-insight-and-market-forecast\">KEYTRUDA<\/a>, an anti-PD-1 therapy, enhances the immune system&#8217;s ability to recognize and combat tumor cells. Approved by the FDA in January 2023, it is indicated for stage IB (T2a \u22654 cm), II, or IIIA NSCLC patients after adjuvant chemotherapy. KEYTRUDA is approved for both adjuvant and metastatic settings, regardless of PD-L1 expression, making it a comprehensive option for NSCLC treatment.<\/li>\n\n\n\n<li><strong>LIBTAYO (cemiplimab-rwlc)<\/strong> \u2013 <strong>Regeneron Pharmaceuticals<\/strong><strong><br><\/strong>LIBTAYO, a fully human monoclonal antibody targeting PD-1, was approved in November 2022 for use with platinum-based chemotherapy in first-line treatment of advanced NSCLC without EGFR, ALK, or ROS1 aberrations. It can also be prescribed as monotherapy for patients with high PD-L1 expression, expanding its utility for various patient profiles.<\/li>\n\n\n\n<li><strong>OPDIVO (nivolumab)<\/strong> \u2013 <strong>Bristol Myers Squibb<\/strong><strong><br><\/strong>In October 2024, Opdivo was approved for resectable NSCLC without EGFR mutations or ALK rearrangements. It is used in combination with platinum-doublet chemotherapy as a neoadjuvant treatment and as monotherapy after surgery.<\/li>\n\n\n\n<li><strong>TAGRISSO (osimertinib)<\/strong> \u2013 <strong>AstraZeneca<\/strong><strong><br><\/strong>Approved in September 2024, <a href=\"https:\/\/www.delveinsight.com\/report-store\/tagrisso-drug-insight-and-market-forecast\">TAGRISSO<\/a> treats unresectable Stage III EGFR-mutated NSCLC in patients without disease progression after chemoradiation therapy. It significantly prolongs progression-free survival for patients with specific EGFR mutations.<\/li>\n\n\n\n<li><strong>RYBREVANT (amivantamab-vmjw)<\/strong> \u2013 <strong>Johnson &amp; Johnson<\/strong><strong><br><\/strong>RYBREVANT was approved in 2024 for use with standard chemotherapy in patients with EGFR exon 19 deletions or L858R substitution mutations. Another approval includes its use with LAZCLUZE\u2122 for first-line treatment in patients with advanced NSCLC harboring these genetic abnormalities.<\/li>\n\n\n\n<li><strong>IMFINZI (durvalumab)<\/strong> \u2013 <strong>AstraZeneca<\/strong><strong><br><\/strong>Approved in August 2024, Imfinzi is used with chemotherapy for early-stage NSCLC (IIA-IIIB) without EGFR mutations or ALK rearrangements. This regimen includes treatment before surgery and adjuvant monotherapy afterward, reducing recurrence, progression, or death by 32%.<\/li>\n<\/ol>\n\n\n\n<p>These advancements underscore the growing arsenal of targeted therapies and immunotherapies in the NSCLC market, improving survival outcomes and addressing diverse patient needs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"In_the_NSCLC_Pipeline\"><\/span><strong>In the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight\"><strong>NSCLC Pipeline<\/strong><\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>At present, there are several emerging therapies in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market?utm_source=blog&amp;utm_campaign=vinita\">Non-small cell lung cancer market<\/a> are Zipalertinib, YK-029A, TAS3351, NVL-330, JS-113, JANX-008, IN-119873, and others which target different types of mutations and form the major<a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\"> NSCLC treatment option<\/a> in the Non-small cell lung cancer market.<\/p>\n\n\n\n<p>Even though the Non-small cell lung cancer market constitutes a<a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-pipeline-insight?utm_source=blog&amp;utm_campaign=vinita\"> robust pipeline<\/a>, the cost-effectiveness of targeted therapies comes out as a great dejecting factor which is a major barrier in the growth of non-small cell lung cancer market. Key players such as <strong>Merck &amp; Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG,<\/strong> and others are involved in developing drugs for Non-small cell lung cancer (NSCLC) that are responsible for the change in dynamics of the Non-small cell lung cancer (NSCLC) market by 2032. In addition to the key companies, hikes in healthcare spending, and early diagnosis due to a better understanding of the disease are other factors driving the NSCLC market forward.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1024x194.jpg\" alt=\"Non-Small Cell Lung Cancer Market Outlook\" class=\"wp-image-30473\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1024x194.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-300x57.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-150x28.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-768x145.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook-1536x291.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/29181606\/Non-Small-Cell-Lung-Cancer-Market-Outlook.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after a cancer diagnosis was estimated [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30476,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[56,96,130,228,985,17967,2734,345,365,395,12556,12555,12554,6732,12557,423,1111,12559,12558,12560,431,460,524,533,18284,17907,2792,18285],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-9262","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-abbvie","tag-astrazeneca","tag-bristol-myers-squibb","tag-eli-lilly","tag-glaxosmithkline","tag-imfinzi","tag-johnson-and-johnson","tag-keytruda","tag-lung-cancer","tag-merck","tag-non-small-cell-lung-cancer-epidemiology","tag-non-small-cell-lung-cancer-market","tag-non-small-cell-lung-cancer-market-insights","tag-non-small-cell-lung-cancer-pipeline","tag-non-small-cell-lung-cancer-treatment-market","tag-novartis","tag-nsclc","tag-nsclc-epidemiology","tag-nsclc-market","tag-nsclc-pipeline","tag-opdivo","tag-pfizer","tag-roche","tag-sanofi","tag-tagrisso","tag-takeda-pharmaceuticals","tag-tecentriq","tag-vizimpro","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Non-Small Cell Lung Cancer Market - NSCLC Market - DelveInsight<\/title>\n<meta name=\"description\" content=\"Discover key insights on Non-small cell lung cancer (NSCLC), including diagnosis, treatments, and emerging market trends.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Non-Small Cell Lung Cancer Market - NSCLC Market - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Discover key insights on Non-small cell lung cancer (NSCLC), including diagnosis, treatments, and emerging market trends.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T12:49:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-02T04:59:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Non-Small Cell Lung Cancer Market - NSCLC Market - DelveInsight","description":"Discover key insights on Non-small cell lung cancer (NSCLC), including diagnosis, treatments, and emerging market trends.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2","og_locale":"en_US","og_type":"article","og_title":"Non-Small Cell Lung Cancer Market - NSCLC Market - DelveInsight","og_description":"Discover key insights on Non-small cell lung cancer (NSCLC), including diagnosis, treatments, and emerging market trends.","og_url":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-29T12:49:53+00:00","article_modified_time":"2024-12-02T04:59:06+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2","url":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2","name":"Non-Small Cell Lung Cancer Market - NSCLC Market - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses.png","datePublished":"2024-11-29T12:49:53+00:00","dateModified":"2024-12-02T04:59:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Discover key insights on Non-small cell lung cancer (NSCLC), including diagnosis, treatments, and emerging market trends.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses.png","width":466,"height":284,"caption":"Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/29183025\/Novel-Mutation-Targeting-Therapies-in-the-Horizon-to-Relieve-the-Global-Healthcare-Burden-NSCLC-Poses-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Imfinzi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NSCLC Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NSCLC Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">NSCLC Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Tagrisso<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Takeda Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Tecentriq<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Vizimpro<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Imfinzi<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Market Insights<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">NSCLC Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">NSCLC Market<\/span>","<span class=\"advgb-post-tax-term\">NSCLC Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Tagrisso<\/span>","<span class=\"advgb-post-tax-term\">Takeda Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Tecentriq<\/span>","<span class=\"advgb-post-tax-term\">Vizimpro<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 29, 2024","modified":"Updated on Dec 2, 2024"},"absolute_dates_time":{"created":"Posted on Nov 29, 2024 6:19 pm","modified":"Updated on Dec 2, 2024 10:29 am"},"featured_img_caption":"Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9262"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9262\/revisions"}],"predecessor-version":[{"id":30494,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9262\/revisions\/30494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30476"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9262"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9262"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}